NGM-438

• Description:

  NGM-438 is a humanized IgG1 monoclonal antibody targeting LAIR1. NGM438 reversed collagen-induced immune suppression in myeloid cells and promoted anti-PD1 mAb-driven T cell responses in immune cell-based functional assays[1].

• UNSPSC:

  12352203

• Target:

  MMP

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Cancer

• Purity:

  99.74

• Molecular Weight:

  (144.92 kDa)

• References & Citations:

  [1]Sisi He, et al. Preclinical development of NGM438, a novel anti-LAIR1 antagonist monoclonal antibody for the treatment of collagen-rich solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA) : AACR; Cancer Res 2022;82 (12_Suppl) :Abstract nr LB219.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  -80°C

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Phase 1